Differences in prescribing between GPs. Impact of the cooperation with pharmacists and impact of visits from pharmaceutical industry representatives

Family Practice

Volumn 22, Issue 6, 2005, Pages 624-630

  Muijrers, Paul E M ^a   Grol, Richard P T M ^b,e   Sijbrandij, Jildou ^b   Janknegt, Rob ^c   Knottnerus, J André ^d  

^a CZ Health Insurance Company   (Netherlands)

^b MAASTRICHT UNIVERSITY   (Netherlands)

^c Sittard Geleen Heerlen   (Netherlands)

^d MAASTRICHT UNIVERSITY   (Netherlands)

^e RADBOUD UNIVERSITY NIJMEGEN   (Netherlands)

Author keywords

Co operation; GP; Indicators; Pharmaceutical industry; Pharmacist

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; ANTIDIABETIC AGENT; ATENOLOL; BENZODIAZEPINE DERIVATIVE; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BETAMETHASONE DIPROPIONATE; BETAMETHASONE VALERATE; CAPTOPRIL; CHLOROTHIAZIDE; CORTICOSTEROID; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EAR DROPS; ENALAPRIL; FERROUS SULFATE; FLUMETASONE PIVALATE; FLUOCINONIDE; HISTAMINE H2 RECEPTOR ANTAGONIST; HYDROCHLOROTHIAZIDE; HYDROCORTISONE BUTYRATE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMIDAZOLE; MEBEVERINE; METFORMIN; METOPROLOL; ORAL CONTRACEPTIVE AGENT; PROTON PUMP INHIBITOR; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TOLBUTAMIDE; TRIAMCINOLONE ACETONIDE; UNINDEXED DRUG;

ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG DOSE REGIMEN; DRUG INDUSTRY; GENERAL PRACTITIONER; HEALTH SURVEY; HUMAN; HUMAN EXPERIMENT; LINEAR REGRESSION ANALYSIS; NETHERLANDS; PHARMACEUTICAL CARE; PHARMACIST; PHYSICIAN ATTITUDE; PRESCRIPTION; QUALITY CONTROL; SCORING SYSTEM; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE;

ADULT; COMMERCE; CROSS-SECTIONAL STUDIES; DRUG INDUSTRY; FEMALE; HUMANS; MALE; MIDDLE AGED; NATIONAL HEALTH PROGRAMS; NETHERLANDS; PHYSICIAN'S PRACTICE PATTERNS; PHYSICIANS, FAMILY;

EID: 30744437921     PISSN: 02632136     EISSN: None     Source Type: Journal    
DOI: 10.1093/fampra/cmi074     Document Type: Article

References (25)

1. Van der Heide H, Tinke JL. Facts and figures, cost development of pharmaceutical aid. The Hague, The Netherlands: Foundation for Pharmaceutical Statistics; 1999. http://www.sfk.nl (accessed 1 Nov 2004).
2. Linjakumpu T, Hartikainen S, Klaukka T, Veijola J, Kivela SL, Isoaho R. Use of medications and polypharmacy are increasing among the elderly. J Clin Epidemiol 2002; 55(8): 809-817.
3. Bero LA, Grilli R, Grimshaw JM, Harvey E, Oxman AD, Thomson MA. Closing the gap between research and practice: An overview of systematic reviews of interventions to promote the implementation of research findings. The Cochrane Effective Practice and Organization of Care Review Group. Br Med J 1998; 317: 465-468.
4. Bjerrum L, Sogaard J, Hallas J, Kragstrup J. Polypharmacy in general practice: Differences between practitioners. Br J Gen Pract 1999; 49(440): 195-198.
5. Watkins C, Harvey I, Carthy P, Moore L, Robinson E, Brawn R. Attitudes and behaviour of general practitioners and their prescribing costs: A national cross sectional survey. Qual Saf Health Care 2003; 12(1): 29-34.
6. Cantrill JA, Sibbald B, Buetow S. Indicators of the appropriateness of long-term prescribing in general practice in the United Kingdom: consensus development, face and content validity, feasibility, and reliability. Qual Health Care 1998; 7(3): 130-135.
7. Muijrers PEM, Janknegt R, Sijbrandij J, Grol RPTM, Knottnerus JA. Prescribing indicators, development and validation of guideline-based prescribing indicators as an instrument to measure the variation in the prescribing behaviour of general practitioners. Eur J Clin Pharmacol 2004; 60(10): 739-746.
8. Beney J, Bero LA, Bond C. Expanding the roles of outpatient pharmacists: effects on health services utilisation, costs, and patient outcomes (Cochrane Review). In: The Cochrane Library, Issue 2, 2003. 2001. Oxford: Update Software.
9. Krska J, Cromarty JA, Arris F, Jamieson D, Hansford D, Duffus PR et al. Pharmacist-led medication review in patients over 65: A randomized, controlled trial in primary care. Age Ageing 2001; 30(3): 205-211.
10. Bernsten C, Bjorkman I, Caramona M, Crealey G, Frokjaer B, Grundberger E et al. Improving the well-being of elderly patients via community pharmacy-based provision of pharmaceutical care: A multicentre study in seven European countries. Drugs Aging 2001; 18: 63-77.
11. Sellors J, Kaczorowski J, Sellors C, Dolovich L, Woodward C, Willan A et al. A randomized controlled trial of a pharmacist consultation program for family physicians and their elderly patients. Can Med Assoc J 2003; 169(1): 17-22.
12. Kocken GA. Medication discussion groups in the Netherlands: Five years of experience. Med Educ 1999; 33(5): 390-393.
13. Bradley CP, Taylor RJ, Blenkinsopp A. Primary care, opportunities and threats. Developing prescribing in primary care. Br Med J 1997; 314: 744-747.
14. Muijrers PEM, Knottnerus JA, Sijbrandij J, Janknegt R, Grol RPTM. Changing relationships: Attitudes and opinions of general practitioners and pharmacists regarding the role of the community pharmacist. Pharm World Sci 2003; 25(5): 235-241.
15. Hughes CM, McCann S. Perceived interprofessional barriers between community pharmacists and general practitioners: A qualitative assessment. Br J Gen Pract 2003; 53(493): 600-606.
16. Howard M, Trim K, Woodward C, Dolovich L, Sellors C, Kaczorowski J et al. Collaboration between community pharmacists and family physicians: lessons learned from the Seniors Medication Assessment Research Trial. J Am Pharm Assoc 2003; 43(5): 566-572.
17. Edmunds J, Calnan MW. The reprofessionalisation of community pharmacy? An exploration of attitudes to extended roles for community pharmacists amongst pharmacists and General Practioners in the United Kingdom. Soc Sci Med 2001; 53(7): 943-955.
18. Spencer JA, Edwards C. Pharmacy beyond the dispensary: General practitioners' views. Br Med J 1992; 304: 1670-1672.
19. Nathan A, Sutters CA. A comparison of community pharmacists' and general practitioners' opinions on rational prescribing, formularies and other prescribing related issues. J R Soc Health 1993; 113(6): 302-307.
20. Thomson O'Brien MA, Oxman AD, Davis DA, Haynes RB, Freemantle N, Harvey EL. Educational outreach visits: Effects on professional practice and health care outcomes (Cochrane Review). In: The Cochrane Library, Issue 3, 2004. Oxford: Update Software.
21. Prosser H, Almond S, Walley T. Influences on GPs' decision to prescribe new drugs-the importance of who says what. Fam Pract 2003; 20(1): 61-68.
22. Wazana A. Physicians and the pharmaceutical industry: Is a gift ever just a gift? J Am Med Assoc 2000; 283(3): 373-380.
23. Van Dijk L, Barnhoorn H, De Bakker D. Het Farmacotherapie Overleg in 1999, stand van zaken en effecten op voorschrijven [Pharmaco-therapeutic audit meeting in 1999, stand at present and effects on prescribing]. Nivel, Utrecht; 2001.
24. Watkins C, Moore L, Harvey I, Carthy P, Robinson E, Brawn R. Characteristics of general practitioners who frequently see drug industry representatives: National cross sectional study. Br Med J 2003; 326(7400): 1178-1179.
25. Holland R, Lenaghan E, Harvey I, Smith R, Shepstone L, Lipp A et al. Does home based medication review keep older people out of hospital? The HOMER randomised controlled trial. Br Med J 2005; 330(7486): 293-297.